Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective

Abstract Background Approximately 97% of global deaths due to RSV occur in low- and middle-income countries (LMICs). Until recently, the only licensed preventive intervention has been a shortacting monoclonal antibody (mAb), palivizumab (PVZ) that is expensive and intensive to administer, making it...

全面介紹

書目詳細資料

發表在:	BMC Medicine
Main Authors:	Rachel Wittenauer, Clint Pecenka, Ranju Baral
格式:	Article
語言:	英语
出版:	BMC 2023-03-01
主題:	Respiratory syncytial virus Cost-of-illness Cost-effectiveness Low- and middle-income countries Systematic review
在線閱讀:	https://doi.org/10.1186/s12916-023-02792-z